禾榮科技
HomeKnowledgeJournal[Journal] Development of a tumor control probability model for boron neutron capture therapy of head and neck cancer

[Journal] Development of a tumor control probability model for boron neutron capture therapy of head and neck cancer

Journal

2024-02-29

Back

Development of a tumor control probability model for boron neutron capture therapy of head and neck cancer

 

Fang-Ying Hsu 1, Yen-Wan Hsueh Liu 1 2, Tzung-Yi Lin 2, Ling-Wei Wang 3 4

 

1Institute of Nuclear Engineering and Science, National Tsing Hua University, Hsinchu, Taiwan.

2Research and Development Center, Heron Neutron Medical Corporation, Zhubei, Taiwan.

3Department of Heavy Particles and Radiation Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.

4School of Medicine, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.

  

Abstract

 The tumor control probability (TCP) model has been used for estimating the response of the radiation (photon) therapy for a given treatment dose (distribution). In Taiwan, boron neutron capture therapy (BNCT) is still at the stage of the clinical trials without standard dose prescription. In this study, universal survival curve (USC) model was selected as the TCP model for BNCT. The tumor response and dose distribution from protocol I of the clinical trial of the recurrent head and neck (H&N) cancer conducted by Taipei Veterans General Hospital and National Tsing Hua University were used to verify the TCP model established in this study. The results showed that, using the USC model as a biological model of dose conversion, the TCP calculated by the generalized Equivalent Uniform Dose (gEUD)-based TCP model can be used to well correlate the relationship between the tumor response and dose distribution of the patients of recurrent H&N cancer. The result shows that 25% and 60% of TCP correspond to partial response and complete response of H&N cancer, respectively. This study also indicated that, when BNCT was used to treat recurrent H&N cancer, the minimum dose was an important factor on the efficacy of the treatment. Minimum dose of 18 Gy-w corresponds to at least 60% of TCP.